Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 2/20 | 0.46 |
| ▸ | CCNC | P24863 | 1/20 | 0.40 |
| ▸ | CDK8 | P49336 | 1/20 | 0.40 |
| ▸ | CA12 | O43570 | 5/20 | 0.39 |
| ▸ | CA1 | P00915 | 5/20 | 0.39 |
| ▸ | CA2 | P00918 | 5/20 | 0.39 |
| ▸ | CA9 | Q16790 | 5/20 | 0.39 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.38 |
| ▸ | HRH1 | P35367 | 7/20 | 0.38 |
| ▸ | HRH2 | P25021 | 6/20 | 0.38 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.38 |
| ▸ | BRD4 | O60885 | 1/20 | 0.37 |
| ▸ | PRKAA2 | P54646 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3423966 | 0.89 | SIGMAR1 (0.45) | KCNH2CCNCCDK8CA1CA2 | |
| SCHEMBL2954489 | 0.89 | KCNH2 (0.51) | KCNH2CA12CA1CA2CA9 | |
| SCHEMBL2964384 | 0.88 | KCNH2 (0.56) | KCNH2CA12CA1CA2CA9 | |
| SCHEMBL6150660 | 0.88 | SIGMAR1 (0.47) | CA1CA2SIGMAR1 | |
| SCHEMBL3128796 | 0.87 | KCNH2 (0.51) | KCNH2CCNCCDK8CA12CA1 | |
| SCHEMBL2963406 | 0.85 | HRH3 (0.49) | KCNH2HRH1HRH2HRH3 | |
| SCHEMBL3129914 | 0.84 | KCNH2 (0.54) | KCNH2CA12CA1CA2CA9 | |
| SCHEMBL3126044 | 0.78 | KCNH2 (0.45) | KCNH2CCNCCDK8HRH3 | |
| SCHEMBL4128200 | 0.78 | CA12 (0.50) | KCNH2CA12CA1CA2CA9 | |
| SCHEMBL1618250 | 0.77 | DRD2 (0.45) | KCNH2CCNCCDK8SIGMAR1PRKAA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060074080-A1 | Combination product comprising melagatran and an anti-arrhythmic oxabispidenes | ASTRAZENECA AB (SE) | 2006-04-06 | — | — | US | disclosed |
| US-20060052314-A1 | Pharmaceutical combination | ASTRAZENECA AB (SE) | 2006-03-09 | — | — | US | disclosed |
| EP-1503782-A1 | A COMBINATION PRODUCT COMPRISING MELAGATRAN AND AN ANTI-ARRHYTHMIC OXABISPIDENES | AstraZeneca AB (SE) | 2005-02-09 | — | — | EP | disclosed |
| EP-1503783-A1 | A COMBINATION PRODUCT COMPRISING AN ANTI-COAGULANT AND ANTI-ARRHYTHMIC OXABISPIDENES | AstraZeneca AB (SE) | 2005-02-09 | — | — | EP | disclosed |
| WO-2003092720-A1 | A COMBINATION PRODUCT COMPRISING AN ANTI-COAGULANT AND ANTI-ARRHYTHMIC OXABISPIDENES | ASTRAZENECA AB (SE) | 2003-11-13 | — | — | WO | disclosed |
| WO-2003092721-A1 | A COMBINATION PRODUCT COMPRISING MELAGATRAN AND AN ANTI-ARRHYTHMIC OXABISPIDENES | ASTRAZENECA AB (SE) | 2003-11-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060052314-A1 | Pharmaceutical combination | F2, TNNT2, WFS1 | KCNH2 847/4885CCNC 323/4885CDK8 830/4885 |
| US-20060074080-A1 | Combination product comprising melagatran and an anti-arrhythmic oxabispidenes | O60361, KCNH1, WNT3A | KCNH2 47/4885CCNC 481/4885CDK8 526/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.